Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (002932.SZ)
CNY 18.76
(-0.74%)
CNY 18.76
(-0.74%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 749.53 Million CNY | -92.88% |
| 2022 | 10.53 Billion CNY | 272.12% |
| 2021 | 2.82 Billion CNY | 195.05% |
| 2020 | 959.09 Million CNY | 429.43% |
| 2019 | 181.15 Million CNY | 2.71% |
| 2018 | 176.38 Million CNY | 6.82% |
| 2017 | 165.12 Million CNY | 17.13% |
| 2016 | 140.97 Million CNY | 47.87% |
| 2015 | 95.34 Million CNY | 64.94% |
| 2014 | 57.8 Million CNY | 122.77% |
| 2013 | 25.94 Million CNY | 265.66% |
| 2012 | 7.09 Million CNY | 482.57% |
| 2011 | 1.21 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 60.65 Million CNY | -50.93% |
| 2024 Q2 | 92.9 Million CNY | 53.17% |
| 2024 Q3 | 71.05 Million CNY | -23.21% |
| 2023 Q3 | 88.36 Million CNY | -46.5% |
| 2023 Q4 | 123.6 Million CNY | 39.88% |
| 2023 FY | 749.53 Million CNY | -92.88% |
| 2023 Q1 | 372.4 Million CNY | -87.83% |
| 2023 Q2 | 165.15 Million CNY | -55.65% |
| 2022 Q4 | 3.06 Billion CNY | 38.06% |
| 2022 Q2 | 2.76 Billion CNY | 11.21% |
| 2022 Q1 | 2.48 Billion CNY | 178.99% |
| 2022 FY | 10.53 Billion CNY | 272.12% |
| 2022 Q3 | 2.21 Billion CNY | -19.86% |
| 2021 Q1 | 676.95 Million CNY | 112.26% |
| 2021 Q3 | 796.96 Million CNY | 71.62% |
| 2021 Q2 | 464.38 Million CNY | -31.4% |
| 2021 Q4 | 891.51 Million CNY | 11.86% |
| 2021 FY | 2.82 Billion CNY | 195.05% |
| 2020 Q2 | 332.01 Million CNY | 1062.83% |
| 2020 Q4 | 318.93 Million CNY | 14.07% |
| 2020 FY | 959.09 Million CNY | 429.43% |
| 2020 Q1 | 28.55 Million CNY | -31.04% |
| 2020 Q3 | 279.6 Million CNY | -15.78% |
| 2019 Q2 | 54.77 Million CNY | 16.33% |
| 2019 Q1 | 47.08 Million CNY | 7.19% |
| 2019 FY | 181.15 Million CNY | 2.71% |
| 2019 Q4 | 41.4 Million CNY | 9.27% |
| 2019 Q3 | 37.89 Million CNY | -30.82% |
| 2018 Q2 | 60.07 Million CNY | 58.81% |
| 2018 Q1 | 37.82 Million CNY | -20.86% |
| 2018 FY | 176.38 Million CNY | 6.82% |
| 2018 Q4 | 43.92 Million CNY | 27.11% |
| 2018 Q3 | 34.55 Million CNY | -42.47% |
| 2017 FY | 165.12 Million CNY | 17.13% |
| 2017 Q1 | 30.48 Million CNY | -17.62% |
| 2017 Q3 | 33.39 Million CNY | -37.51% |
| 2017 Q4 | 47.79 Million CNY | 43.1% |
| 2017 Q2 | 53.44 Million CNY | 75.31% |
| 2016 Q3 | 37 Million CNY | 10.52% |
| 2016 FY | 140.97 Million CNY | 47.87% |
| 2016 Q1 | 33.48 Million CNY | 27.47% |
| 2016 Q4 | 37 Million CNY | 0.0% |
| 2016 Q2 | 33.48 Million CNY | 0.0% |
| 2015 Q2 | 21.4 Million CNY | -0.0% |
| 2015 Q4 | 26.26 Million CNY | 0.0% |
| 2015 FY | 95.34 Million CNY | 64.94% |
| 2015 Q1 | 21.4 Million CNY | 19.52% |
| 2015 Q3 | 26.26 Million CNY | 22.73% |
| 2014 Q1 | 10.99 Million CNY | 25.17% |
| 2014 Q3 | 17.9 Million CNY | 62.89% |
| 2014 Q4 | 17.9 Million CNY | 0.0% |
| 2014 Q2 | 10.99 Million CNY | -0.0% |
| 2014 FY | 57.8 Million CNY | 122.77% |
| 2013 Q4 | 8.78 Million CNY | 0.0% |
| 2013 Q2 | 4.19 Million CNY | -0.0% |
| 2013 Q3 | 8.78 Million CNY | 109.58% |
| 2013 FY | 25.94 Million CNY | 265.66% |
| 2013 Q1 | 4.19 Million CNY | 0.0% |
| 2012 FY | 7.09 Million CNY | 482.57% |
| 2011 FY | 1.21 Million CNY | 0.0% |